Rewiring of Integrin Signaling and Cell-cycle Deregulation Drive SMARCB1-Deficient Epithelioid Sarcoma

Epithelioid sarcoma (EPS) is a particularly aggressive form of soft tissue cancer that arises due to a loss of the chromatin-remodeling protein SMARCB1. The exact mechanisms behind EPS have been difficult to pinpoint. However, a recent study has uncovered key dependencies on integrin signaling and CDKs as driving forces behind the disease.

By using CRISPR technology, researchers discovered that disrupting the integrin subunit alpha V (ITGAV) signaling pathway led to altered epithelioid cluster formation and reduced MYC expression. When SMARCB1 was re-introduced, it replicated these effects, suggesting that SMARCB1 loss is specifically responsible for repressing certain integrin subunits while maintaining an ITGAV-centered survival mechanism.

This nuanced behavior is linked to changes in the BAF complex's occupancy. Further studies on EPS cell lines and primary tumors revealed a common occurrence of genetic or epigenetic inactivation of CDKN2A/p16, a gene essential for regulating the cell cycle. This finding indicates that the loss of cell-cycle control is a crucial accomplice in the development of EPS, offering a promising target for developing targeted therapies through CDK4/6 inhibition.

Ultimately, these insights shed light on the central oncogenic program in EPS, emphasizing the importance of integrin-driven signaling and cell-cycle deregulation as critical factors in this devastating disease.